Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 7/20 | 0.54 |
| ▸ | HINT1 | P49773 | 6/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702978 | 0.83 | TYMP (0.68) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL1738400 | 0.83 | TYMP (0.68) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL18042134 | 0.83 | TYMP (0.68) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL313747 | 0.82 | TYMP (0.62) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL313746 | 0.82 | TYMP (0.62) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL21905181 | 0.82 | TYMP (0.67) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL6460952 | 0.82 | TYMP (0.63) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL6420722 | 0.81 | TYMP (0.79) | TYMPHINT1HPGDGSK3ARPS6KA3 | |
| SCHEMBL17223100 | 0.80 | TYMP (0.64) | TYMPHINT1TAS1R3TAS1R1HPGD | |
| Benzaldehyde SCHEMBL7181882 | 0.80 | TYMP (0.44) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036649-A1 | 2' modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | claimed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0942000-A2 | 2'Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-15 | — | — | EP | claimed |
| EP-0497875-B1 | 2' MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036649-A1 | 2' modified oligonucleotides | DCLRE1B, POLRMT, POLM | TYMP 10/4885HINT1 2360/4885TAS1R3 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.